Spiegelzymes: Sequence Specific Hydrolysis of L-RNA with Mirror Image Hammerhead Ribozymes and DNAzymes

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Wyszko, Eliza ^a   Szymański, Maciej ^a,e   Zeichhardt, Heinz ^b   Müller, Florian ^c   Barciszewski, Jan ^a   Erdmann, Volker A ^d  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Pentafolium Soft ^*  (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBOSE; DNA; DNAZYME; HAMMERHEAD RIBOZYME; NUCLEIC ACID; RIBOSE; SPIEGELZYME; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DNA STRUCTURE; ENZYME ACTIVITY; GENE INTERACTION; GENE TARGETING; HUMAN; HYDROLYSIS; INTERACTIONS WITH DNA; INTERACTIONS WITH RNA; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; RNA SEQUENCE; RNA STRUCTURE; STRUCTURE ANALYSIS;

ANIMALS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; COS CELLS; DEOXYRIBONUCLEASES; DNA, CATALYTIC; HUMANS; HYDROLYSIS; MODELS, MOLECULAR; NUCLEIC ACID CONFORMATION; RIBONUCLEASES; RNA; RNA STABILITY; RNA, CATALYTIC;

EID: 84873839185     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054741     Document Type: Article

References (34)

1. Carothers JM, Szostak JW (2006) In vitro selection of functional oligonucleotides and the origins of biochemical activity. In: The Aptamer Handbook, Functional Oligonuleotides and Their Applications, Ed. S. Klussmann, Wiley-VCH Weinheim.
2. Xu W, Ellington AD, (1996) Anti-peptide aptamers recognize amino sequence and bind a protein epitope. Proc Natl Acad Sci USA 93: 7475-7480.
3. Klussmann S, Nolte A, Bald R, Erdmann VA, Fürste JP, (1996) Mirror-image RNA that binds D-adenosine. Nat Biotechnol 14: 1112-1115.
4. Nolte A, Klussmann S, Bald R, Erdmann VA, Fürste JP, (1996) Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nat Biotechnol 14: 1116-1119.
5. van Rooij E, Olson EN, (2012) MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 11: 860-872.
6. Gaglione M, Messere A, (2010) Recent progress in chemically modified siRNAs. Mini Rev Med Chem 10: 578-595.
7. Eulberg D, Jarosch F, Vonhoff S, Klussmann S (2006) Spiegelmers for Therapeutic Applications. In: The Aptamer Handbook, Functional Oligonucleotides and Their Applications, Ed. S. Klussmann, Wiley-VCH Weinheim.
8. Oney S, Lam RT, Bompiani KM, Blake CM, Quick G, et al. (2009) Development of universal antidotes to control aptamer activity. Nat Med 15: 1224-1228.
9. Robertson DL, Joyce GF, (1990) Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 344: 467-468.
10. Tuerk C, Gold L, (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510.
11. Ellington AD, Szostak JW, (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
12. Kulkarni O, Eulberg D, Selve N, Zöllner S, Allam R, et al. (2009) Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. J Pharmacol Exp Ther 328: 371-377.
13. Ninichuk VS, Clauss S, Kulkarni O, Schmid H, Segerer S, et al. (2008) Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3′PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol. 172: 628-637.
14. Mangasarian A (2011) Noxxon Pharma AG Presentation at Bio-Europe Sprong 2011, 5th Annual International Partnering Conference, Milan, Italy. See also press release by Noxxon Pharma AG, July, 2012.
15. Foster AC, Symons RH, (1987) Self-cleavage of virusoid RNA is performed by the proposed 55-nucleotide active site. Cell 50: 9-16.
16. Ruffner DE, Dahm SC, Uhlenbeck OC, (1989) Studies on the hammerhead RNA self-cleaving domain. Gene 82: 31-41.
17. Hertel KJ, Pardi A, Uhlenbeck OC, Koizumi M, Ohtsuka E, et al. (1992) Numbering system for the hammerhead. Nucleic Acids Res 20: 3252.
18. Wedekind JE, McKay DB, (1998) Crystallographic structures of the hammerhead ribozyme: relationship to ribozyme folding and catalysis. Annu Rev Biophys Biomol Struct 27: 475-502.
19. Hammann C, Lilley DM, (2002) Folding and activity of the hammerhead ribozyme. ChemBioChem 3: 690-700.
20. Fedor MJ, (2009) Comparative enzymology and structural biology of RNA self-cleavage. Annu Rev Biophys 38: 271-299.
21. Scott WG (2010) What can the new hammerhead ribozyme structures teach us about design? in RNA Technologies and Their Applications, Eds: V.A. Erdmann, Jan Barciszewski, Springer, 305-324.
22. Dass CR, Choong PF, Khachigian LM, (2008) DNAzyme technology and cancer therapy: Cleave and let die. Mol Cancer Ther 7: 243-251.
23. Cai H, Santiago FS, Prado-Lourenco L, Wang B, Patrikakis M, et al. (2012) DNAzyme targeting c-jun suppresses skin cancer growth. Sci Transl Med 4: 139ra82.
24. Zaborowska Z, Schubert S, Kurreck J, Erdmann VA, (2005) Deletion analysis in the catalytic region of the 10-23 DNA enzyme. FEBS Lett. 579: 554-558.
25. Vallazzza M, Perbandt M, Klussmann S, Einspahr HM, Erdmann VA, et al. (2004) First look at RNA in L-configuration. Acta Crystallogr.D 60, 1-7.
26. Rypniewski W, Vallazza M, Perbandt M, Klussmann S, Delucas LJ, et al. (2006) The first crystal structure of an RNA racemate. Acta Cryst. D62: 659-664.
27. Bolik S, Rübhausen M, Binder S, Schultz B, Perbandt M, et al. (2007) First experimental evidence for the preferential stabilization of the natural D- over the nonnatural L-confirmation of nucleic acids. RNA 13: 877-880.
28. Becker RC, Oney S, Becker KC, Rusconi CP, Sullenger B, (2007) Nucleic acid aptamers and their complimentary antidotes. Heamostaseologie 27: 378-382.
29. Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, et al. (2002) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419: 90-94.
30. Nimjee SM, Keys JR, Pitoc GA, Quick G, Rusconi CP, et al. (2006) A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 14: 408-415.
31. Wang J, Cao Y, Chen G, Li G, (2009) Regulation of thrombin activity with a bifunctional aptamer and hemin: development of a new anticoagulant and antidote pair. ChemBioChem 10: 2171-2176.
32. Santoro SW, Joyce GF, (1997) A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 94: 4262-4266.
33. Burgess DJ, (2012) Therapeutics: Antitumour potential of catalytic DNA. Nature Rev Cancer 12: 508-509.
34. Martick M, Scott WG (2006) Tertiary contacts distant from the active site prime a ribozyme for catalysis. Cell: 126, 309-320.